DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究  

Clinical research on treating advanced stage hepatocarcinoma with DC-CIK immunotherapy combined with TACE interventional therapy

作　　者：祖余琪 薛平[1] 蒋小峰[1] 温子龙[1] 张大伟[1] 

机构地区：[1]广州医科大学第二附属医院肝胆外科,广州510288

出　　处：《岭南现代临床外科》2014年第5期505-508,共4页Lingnan Modern Clinics in Surgery

基　　金：广东省科技计划项目(编号:2010B031600141)

摘　　要：目的探讨DC-CIK细胞免疫治疗联合介入治疗晚期肝癌的临床疗效。方法选择晚期原发性肝癌患者112例为研究对象,根据患者自愿情况分为TACE联合DC-CIK细胞免疫治疗组(A组,n=64)和TACE治疗组(B组,n=48),观察治疗前后血常规、肿瘤标志物、免疫功能及治疗效果。结果 A组缓解率明显高于B组(78.12%VS 47.92%);治疗前后CD3+、CD4+、CD8+、CD19+、NK、CD3+/CD4+、CD3+/CD8+增加或减少值均高于B组;随访6个月、12个月,A组死亡病例明显低于B组(6.25%VS 16.67%,1.78%VS 12.82%),但两组18个月的死亡病例数比较没有差异。结论 TACE联合DC-CIK细胞免疫治疗一定程度上可改善免疫功能,提高近期疗效。Objective To investigate the clinical effectiveness of transcatheter arterial chemoem- bolization （TACE） combined with DC-CIK in treating advanced stage hepatoearcinoma. Methods 112 patients with advanced stage hepatocarcinoma were included in the study. Among them,64 cases received TACE combined with DC-CIK （group A） and 48 cases underwent TACE alone （group B）. Blood routine, tumor makers, immune function were detected, analyzed in all patients and compared between two groups. Results The serum CD3^＋, CD4^＋, CD8^＋, CD19^＋, NK, CD3^＋/CD4^＋, CD3^＋/ CD8^＋ cells in A group were increased than that in B group （P〈0.05）. The number of patients who were demonstrated remission and partial remission was increased in A group than that in B group（P〈0.05 ）. The death mumber in A group was less than in group at 6 months and 12 months of follow-up and no difference was found at 18 months of follow-up. Conclusion To a certain degree, TACE combined with DC-CIK would improve the immune function,increase in the near future curative effect for patients with advanced stage hepatocareinoma.

关 键 词：晚期肝癌 TACE DC-CIK 肿瘤标志物 免疫功能 

分 类 号：R735.7[医药卫生—肿瘤]